adenoassoci
viru
aav
nonenvelop
singlestrand
dna
viru
member
parvoviru
famili
aav
genom
approxim
kb
size
packag
within
icosahedr
capsid
facilit
viral
entri
suscept
cell
schultz
chamberlain
aavmedi
gene
transfer
success
demonstr
numer
larg
small
anim
model
human
diseas
arnett
et
al
wang
et
al
recombin
aav
raav
vector
thu
consid
prime
candid
use
develop
gene
replac
strategi
raav
vector
limit
small
carri
capac
possess
sever
attract
featur
advantag
use
therapeut
reagent
includ
broad
rang
tissu
tropism
lack
pathogen
schultz
chamberlain
serotyp
numer
variant
aav
identifi
serotyp
demonstr
uniqu
profil
tissu
tropism
util
develop
target
therapi
enhanc
tissu
specif
zincarelli
et
al
vandenbergh
et
al
exampl
exhibit
high
tropism
liver
use
treat
hemophilia
b
via
express
factor
ix
manno
et
al
shown
achiev
high
level
transduct
lung
halbert
et
al
striat
muscl
blankinship
et
al
gregorev
et
al
thu
studi
develop
treatment
diseas
cystic
fibrosi
flott
et
al
halbert
et
al
defici
halbert
et
al
muscular
dystrophi
arnett
et
al
wang
et
al
stabl
transgen
express
transduc
cell
har
treat
diseas
result
genet
defici
howev
signific
obstacl
use
viral
vector
develop
host
immun
respons
transgen
vector
zaiss
muruv
nayak
herzog
raav
genom
one
simplest
viral
gene
therapi
vector
contain
transgen
express
cassett
flank
noncod
viral
invert
termin
repeat
facilit
packag
capsid
assembl
samulski
et
al
viral
gene
encod
within
engin
genom
significantli
reduc
risk
viral
protein
synthesi
within
host
limit
potenti
immunogen
raav
vector
initi
studi
regard
raav
deliveri
demonstr
rel
lack
cellmedi
immun
respons
raav
infect
anim
athanasopoulo
et
al
warrington
herzog
contrast
adenoviru
raav
effici
trigger
strong
acut
inflammatori
respons
result
ineffici
activ
dendrit
cell
antigen
present
cell
influenc
cytotox
immun
respons
zaiss
muruv
factor
thought
contribut
sustain
transgen
express
target
tissu
howev
despit
promis
result
anim
studi
clinic
trial
raav
gene
deliveri
human
fail
demonstr
level
success
result
multipl
studi
indic
capsidspecif
humor
cellmedi
immun
limit
tissu
transduct
lead
gradual
clearanc
transduc
cell
manno
et
al
mingozzi
high
mingozzi
et
al
thu
renew
effort
made
understand
modul
factor
govern
immun
respons
raav
across
multipl
rout
deliveri
evalu
therapeut
construct
deliveri
strategi
larg
anim
model
necessari
step
assess
potenti
gene
replac
therapi
destin
clinic
trial
regard
dog
suitabl
model
physic
challeng
vector
deliveri
larg
volum
tissu
model
potenti
advers
reaction
evolv
mammalian
immun
system
wang
et
al
immun
respons
raav
canin
investig
sever
studi
mount
et
al
wang
et
al
yuasa
et
al
ohshima
et
al
halbert
et
al
haurigot
et
al
other
previous
evalu
raav
deliveri
striat
muscl
yuasa
et
al
gregorev
et
al
ohshima
et
al
observ
signific
humor
cellmedi
immun
util
varieti
raav
serotyp
wang
et
al
yuasa
et
al
ohshima
et
al
howev
canin
use
research
purpos
routin
vaccin
sever
potenti
pathogen
one
canin
parvoviru
cpv
cpv
infect
associ
high
mortal
young
puppi
contagi
patel
helden
high
risk
cpv
infect
necessit
earli
vaccin
major
kennel
like
aav
cpv
member
parvoviru
famili
share
signific
sequenc
ident
aav
famili
member
follow
immun
respons
gener
cpv
vaccin
potenti
crossreact
member
parvoviru
famili
includ
aav
thu
import
consid
influenc
cpv
vaccinerel
immun
raavdirect
immun
respons
canin
well
influenc
earli
exposur
viru
vaccin
constitu
matur
mammalian
immun
system
studi
investig
immun
respons
deliveri
cpvvaccin
canin
evalu
multipl
vaccin
regimen
mous
model
cpvvaccin
addit
explor
influenc
earli
immun
respons
repeat
adulthood
canin
parvovirusvaccin
potenti
stimul
product
antibodi
crossreact
raav
may
contribut
raavdirect
immun
respons
previous
observ
canin
wang
et
al
yuasa
et
al
ohshima
et
al
address
concern
test
serum
cohort
wildtyp
wt
beagl
vaccin
follow
standard
vaccin
regimen
includ
three
separ
intramuscular
cpvvaccin
age
week
serum
collect
week
age
evalu
crossreact
neutral
antibodi
figur
assay
result
demonstr
neutral
effici
serum
cpvvaccin
anim
minim
strongest
serum
dilut
test
less
inhibit
observ
follow
initi
serum
collect
dog
treat
via
intravascular
inject
vector
genomeskg
serum
sampl
analysi
week
later
expect
exposur
capsid
elicit
strong
neutral
antibodi
respons
figur
prior
cpvvaccin
prevent
transduct
skelet
muscl
publish
gregorev
et
al
wang
et
al
also
perform
seri
western
analyz
whether
cpv
vaccin
gener
antibodi
cross
react
aav
capsid
serum
sampl
collect
two
group
dog
figur
group
sera
collect
five
cpvvaccin
dog
age
month
old
postcpv
preraav
sampl
collect
week
intramuscular
im
inject
vector
group
sera
collect
pup
n
prior
cpv
vaccin
follow
collect
month
cpvvaccin
week
im
inject
figur
show
repres
data
gener
two
group
essenti
ident
result
seen
dog
precpv
serum
isol
three
dog
group
show
obviou
reactiv
parvovir
capsid
western
analysi
parvoviru
capsid
detect
postparvo
preraav
serum
use
serum
abl
detect
background
bsa
use
neg
control
expect
serum
collect
treatment
show
strong
reactiv
wherea
parvovir
signal
remain
similar
strength
observ
prior
raav
inject
togeth
data
suggest
cpv
vaccin
gener
antibodi
detect
crossreact
raav
cpvvaccin
develop
market
multipl
agenc
thu
vaccin
reagent
time
administr
vari
kennel
kennel
import
recogn
variat
vaccin
regimen
could
influenc
natur
immun
respons
may
appropri
gener
result
obtain
singl
vaccin
regimen
rel
small
cohort
anim
result
vaccin
beagl
provid
insight
regard
immun
respons
cpvvaccin
crossreact
howev
studi
limit
issu
inher
larg
anim
model
ethic
consider
high
cost
necessit
use
small
number
anim
thu
impract
effect
assess
multipl
vaccin
regimen
canin
model
consider
factor
continu
remaind
vaccin
studi
mous
amen
larger
sampl
size
addit
smaller
mass
facilit
administr
higher
dose
per
kilogram
achiev
bodywid
transduct
skelet
muscl
blankinship
et
al
relev
therapeut
dose
level
signific
differ
exist
canin
murin
immun
system
mous
util
extens
model
system
studi
vaccin
respons
autoimmun
aspect
mammalian
immunolog
thu
common
immun
system
anim
model
predict
result
regard
cpvvaccin
gener
potenti
immun
respons
mous
may
also
applic
canin
model
mice
vaccin
follow
two
differ
regimen
repres
commonli
employ
kennel
figur
regimen
util
reagent
equival
vaccin
administ
cohort
beagl
consist
dose
pv
modifi
live
cpv
vaccin
coupl
intra
upper
respiratori
vaccin
direct
adenoviru
parainfluenza
bordetella
bronchiseptica
regimen
consist
combin
two
commerci
vaccin
plu
max
contain
attenu
cpv
parainfluenza
adenoviru
canin
coronaviru
canin
distemp
two
vaccin
given
togeth
initi
dose
follow
singl
addit
dose
plu
week
later
eight
week
postvaccin
serum
collect
cohort
analyz
crossreact
capsid
vaccin
anim
exhibit
slightli
elev
neutral
antibodi
respons
compar
unvaccin
mice
figur
howev
differ
statist
signific
highest
serum
concentr
three
cohort
mice
inject
carri
human
placent
alkalin
phosphatas
hplap
report
gene
vector
administ
via
iv
inject
vg
im
inject
vg
dual
inject
method
employ
ensur
maximum
present
capsid
monitor
immun
cell
interstiti
intravascular
compart
one
month
postraav
inject
serum
sampl
striat
muscl
tissu
collect
analysi
figur
transgen
express
vector
genom
quantifi
across
differ
group
signific
differ
hplap
enzymat
activ
genom
copi
number
found
either
two
vaccin
regimen
unvaccin
control
mice
figur
addit
signific
cellular
inflammatori
respons
observ
transduc
muscl
isol
vaccin
unvaccin
mice
figur
suggest
cpvvaccin
contribut
chronic
inflammatori
infiltr
raavtransduc
muscl
expect
neutral
antibodi
gener
follow
inject
respons
cpvvaccin
mice
significantli
differ
compar
control
anim
immun
system
young
mammal
immatur
neonat
exposur
antigen
alway
elicit
type
immun
respons
adult
review
jaspan
et
al
diminish
cytotox
cell
respons
presenc
circul
matern
antibodi
result
impair
induct
memori
cell
persist
infect
newborn
adkin
et
al
addit
tolerogen
respons
antigen
initi
neonat
morein
et
al
verhasselt
could
theoret
har
facilit
repeat
administr
therapeut
vector
thu
possibl
earli
vaccin
could
modul
immun
respons
raav
infect
permiss
manner
investig
prospect
vaccin
mice
either
day
age
vector
deliv
intraperiton
dose
vg
per
mous
figur
serum
collect
week
postvaccin
neutral
activ
quantifi
prior
im
inject
vg
left
tibiali
anterior
ta
cohort
mice
gener
signific
neutral
antibodi
respons
neonat
vaccin
figur
howev
neutral
activ
day
vaccin
cohort
significantli
lower
compar
day
cohort
addit
anim
day
cohort
demonstr
greater
degre
individu
variabl
neutral
activ
may
relat
differ
immun
system
matur
develop
newborn
old
mice
interestingli
transduct
skelet
muscl
significantli
impact
earli
vaccin
either
cohort
despit
presenc
circul
antibodi
figur
result
suggest
immun
respons
initi
vaccin
neonat
mice
may
repres
either
weak
ineffect
primari
immun
respons
reinfect
may
instead
indic
toler
respons
potenti
remain
permiss
viral
infect
upon
reexposur
adulthood
previous
shown
im
inject
raav
stimul
robust
humor
immun
respons
suffici
prevent
skelet
muscl
transduct
upon
subsequ
exposur
vector
serotyp
burger
et
al
rivier
et
al
sabatino
et
al
shown
mice
respond
posit
first
im
inject
import
determin
whether
permiss
state
would
persist
repeat
exposur
adulthood
evalu
whether
mice
develop
function
toler
day
day
cohort
given
addit
im
inject
vg
contralater
ta
muscl
serum
collect
immedi
prior
inject
neutral
activ
quantifi
figur
cohort
show
strong
neutral
antibodi
respons
significantli
enhanc
compar
respons
obtain
first
bleed
figur
signific
differ
neutral
activ
observ
vaccin
anim
unvaccin
control
addit
neutral
activ
remain
high
even
dilut
serum
concentr
suggest
week
im
inject
enhanc
immun
respons
consist
observ
transduct
contralater
ta
dramat
reduc
limit
small
number
spars
distribut
muscl
fiber
figur
data
indic
mice
remain
permiss
repeat
infect
suggest
success
initi
im
inject
may
relat
weak
primari
immun
respons
rather
induct
toler
immun
respons
raav
vector
emerg
promin
issu
develop
gene
replac
strategi
initi
studi
suggest
rel
lack
immunogen
raav
vector
success
achiev
anim
model
mirror
human
trial
signific
immun
respons
vector
observ
follow
intravascular
deliveri
raav
liver
direct
inject
skelet
muscl
exposur
wildtyp
aav
common
within
human
popul
frequenc
seroposit
aavdirect
neutral
antibodi
approach
nearli
mingozzi
high
preexist
neutral
antibodi
aav
shown
significantli
inhibit
transduct
hepatocyt
clinic
trial
evalu
deliveri
hemophilia
patient
manno
et
al
similar
humor
respons
observ
cystic
fibrosi
gene
therapi
trial
involv
repeat
administr
flott
et
al
disappointingli
major
clinic
trial
result
gradual
loss
transgen
express
deliveri
human
factor
ix
hfix
either
skelet
muscl
kay
et
al
liver
manno
et
al
result
therapeut
level
hfix
subset
patient
hfix
express
eventu
elimin
reduc
nontherapeut
level
particip
anoth
clinic
trial
use
deliv
lipoprotein
lipas
lpl
via
im
inject
patient
lpldefici
mingozzi
et
al
transgen
express
rose
effect
level
rel
short
period
gradual
drop
therapeut
threshold
clinic
trial
deliveri
two
three
patient
respond
well
treatment
wherea
third
patient
fail
demonstr
success
gene
transfer
mendel
et
al
extens
analysi
data
gener
clinic
trial
indic
humor
cellmedi
anticapsid
immun
respons
like
play
signific
role
elimin
transduc
tissu
manno
et
al
mingozzi
et
al
mendel
et
al
signific
immun
respons
observ
sever
studi
raav
deliveri
canin
aspect
canin
immun
respons
mirror
find
human
clinic
trial
includ
detect
capsiddirect
cell
respons
gradual
loss
transgen
express
nonimmunosuppress
anim
ohshima
et
al
observ
strong
inflammatori
respons
cell
infiltr
follow
deliveri
skelet
muscl
though
magnitud
inflammatori
respons
reduc
muscl
addit
previous
shown
inject
immunocompet
anim
result
similar
sequenc
event
anticapsid
immun
respons
led
local
inflamm
clearanc
major
transduc
cell
period
sever
week
wang
et
al
loss
transgen
express
prevent
short
cours
immunosuppress
wang
et
al
raavdirect
immun
respons
also
limit
transgen
express
canin
model
defici
halbert
et
al
studi
rais
concern
regard
immunogen
raav
vector
emphas
need
care
evalu
potenti
immun
respons
raav
deliveri
especi
disord
may
requir
high
vector
dose
system
deliveri
muscular
dystrophi
studi
canin
immun
respons
raav
may
provid
insight
toward
address
immunogen
clinic
trial
import
rule
influenc
cpvvaccin
regard
gener
raavdirect
immun
respons
antibodi
crossreact
demonstr
close
relat
variant
aav
relat
member
parvoviru
famili
patel
helden
addit
shown
cell
receptor
reactiv
epitop
conserv
differ
serotyp
mingozzi
high
mingozzi
et
al
wang
et
al
suggest
cellmedi
respons
may
broadli
reactiv
across
relat
group
viral
vector
observ
low
level
neutral
activ
mous
canin
model
cpvvaccin
serum
dilut
figur
activ
measur
dilut
serum
concentr
western
analysi
serum
parvovaccin
unvaccin
canin
exhibit
enhanc
bind
raav
particl
figur
result
may
indic
presenc
anticpv
antibodi
possess
low
crossreact
affin
crossreact
antibodi
weak
affin
would
requir
higher
concentr
neutral
antibodi
achiev
signific
neutral
dilut
serum
concentr
ineffici
bind
crossreact
antibodi
would
significantli
limit
neutral
activ
character
antibodi
respons
would
necessari
quantifi
affin
strength
identifi
common
epitop
target
crossreact
confirm
howev
import
emphas
cpvvaccin
correl
signific
inhibit
transduct
figur
suggest
low
level
neutral
activ
may
play
role
gener
function
signific
immun
respons
addit
detect
signific
inflammatori
infiltr
observ
chang
muscl
architectur
would
indic
cellmedi
cytotox
respons
figur
b
cpv
vaccin
regimen
util
studi
chosen
reflect
vaccin
regimen
routin
employ
larg
kennel
within
unit
state
bioresourc
varieti
cpv
vaccin
avail
differ
manufactur
avail
differ
region
depend
local
law
intern
licens
market
prefer
patel
helden
regimen
evalu
studi
repres
major
vaccin
compon
use
major
manufactur
thu
result
like
applic
wide
select
vaccin
howev
possibl
subtl
differ
vaccin
vaccin
schedul
could
influenc
immun
respons
addit
studi
evalu
vaccin
larger
number
manufactur
would
necessari
rule
possibl
addit
cpvvaccin
explor
respons
vaccin
neonat
mice
immun
system
newborn
mammal
underdevelop
signific
differ
exist
pattern
b
cell
activ
newborn
adult
newborn
exhibit
gener
defici
adapt
cellular
respons
bia
toward
prolong
immun
adkin
et
al
observ
attribut
influenc
matern
cytokin
hormon
promot
matern
toler
fetal
antigen
cytokin
persist
fetal
circul
influenc
neonat
immun
respons
signific
period
birth
lead
rel
tolerogen
vulner
state
neonat
morein
et
al
regard
newborn
period
repres
time
immun
system
learn
balanc
induct
toler
self
antigen
appropri
reactiv
immun
foreign
pathogen
thu
viral
vector
deliv
development
window
potenti
initi
toler
immun
respons
abil
achiev
success
transduct
follow
repeat
administr
viral
vector
would
advantag
clinic
realm
basic
research
unfortun
repetit
administr
ident
serotyp
ineffect
major
case
due
develop
signific
humor
immun
respons
raav
vector
burger
et
al
rivier
et
al
sabatino
et
al
petri
et
al
specul
earli
vaccin
raav
could
stimul
toler
respons
vector
immatur
immun
system
thu
permit
readministr
adulthood
regard
previou
studi
investig
respons
utero
adenovir
lipshutz
et
al
bouchard
et
al
aav
jerebtsova
et
al
bouchard
et
al
sabatino
et
al
vaccin
mice
studi
limit
im
inject
raav
serotyp
evalu
consid
serotypespecif
transduct
profil
dosag
rout
administr
significantli
influenc
immun
respons
viral
vector
mingozzi
high
petri
et
al
zaiss
muruv
import
empir
determin
immun
respons
vaccin
unfortun
unabl
induc
persist
toler
util
neonat
vaccin
neutral
antibodi
respons
initi
ip
vaccin
inhibit
transduct
first
im
inject
week
age
howev
anim
remain
permiss
transduct
contrari
neutral
activ
significantli
enhanc
follow
first
im
inject
result
nearcomplet
inhibit
transduct
second
im
inject
result
suggest
initi
vaccin
trigger
weak
primari
immun
respons
led
enhanc
secondari
reaction
first
im
inject
howev
without
detail
character
antibodi
respons
rule
exist
partial
toler
specif
viral
epitop
find
consist
previous
observ
follow
utero
deliveri
jerebtsova
et
al
sabatino
et
al
indic
neonat
ip
inject
facilit
repetit
administr
vector
beyond
singl
repeat
inject
summari
evalu
effect
cpv
raav
vaccin
transduct
neutral
antibodi
respons
cpvvaccin
anim
minim
appear
significantli
enhanc
either
humor
cellular
respons
transduct
data
suggest
cpvimmun
signific
compon
immun
respons
canin
support
use
canin
valid
model
character
immun
respons
contrast
vaccin
neonat
mice
lead
signific
immun
respons
prevent
repetit
administr
howev
addit
method
toler
induct
may
warrant
consider
includ
oral
deliveri
verhasselt
thymic
express
viral
protein
chu
et
al
vector
gener
previous
describ
grimm
et
al
cell
cotransfect
packag
plasmid
plasmid
contain
express
cassett
flank
viral
itr
cellular
pellet
supernat
collect
process
microfluid
microfluid
newton
usa
follow
clarif
homogen
filtrat
filter
addit
amersham
hplc
machin
amersham
piscataway
nj
usa
use
affin
purif
hitrap
heparin
column
amersham
column
wash
vector
elut
dialyz
physiolog
ringer
solut
vector
titer
use
cell
transduct
target
southern
analysi
util
determin
number
genomecontain
particl
vector
prepar
anim
studi
perform
accord
guidelin
set
forth
institut
review
offic
univers
washington
mice
bred
anim
facil
mice
given
vaccin
aav
inject
accord
indic
schedul
see
result
vaccin
administ
use
either
intra
galaxi
suppli
intervetscheringplough
anim
health
millsboro
de
usa
plu
pfizer
anim
health
exton
pa
usa
max
boehringeringelheim
vetmedica
inc
st
joseph
mo
usa
intraperiton
administr
deliv
via
either
retroorbit
inject
im
inject
left
ta
muscl
indic
blood
sampl
collect
via
retroorbit
rout
isofluoraneinduc
anesthesia
indic
timepoint
mice
euthan
accord
approv
protocol
tissu
sampl
collect
analysi
vector
genomewel
parvoviru
vaccin
dilut
load
onto
nupag
gel
biorad
usa
gel
transfer
onto
nitrocellulos
membran
biorad
usa
membran
block
nonfat
milk
wv
overnight
incub
serum
dilut
horseradish
peroxidas
hrp
label
rabbit
antidog
ig
use
secondari
antibodi
jackson
immunoresearch
usa
immunoreact
protein
visual
use
ecl
system
amersham
usa
human
embryon
kidney
cell
human
fibrosarcoma
cell
maintain
dulbecco
modifi
eagl
medium
supplement
fetal
bovin
serum
supplement
penicillin
streptomycin
cell
cultur
atmospher
serum
prepar
centrifug
rpm
min
follow
heat
inactiv
min
viru
neutral
assay
done
previous
describ
halbert
et
al
calcedo
et
al
briefli
dilut
genomecontain
particl
per
ml
serum
ad
dilut
viru
achiev
desir
final
serum
dilut
viru
serum
incub
h
ad
cell
plate
cell
per
well
well
plate
previou
day
two
day
follow
infect
plate
transduc
count
fluoresc
activ
cell
sort
fac
cell
transduc
stain
hplap
express
number
posit
cell
per
field
quantifi
muscl
tissu
frozen
liquid
nitrogencool
isopentan
embed
tissuetek
oct
medium
sakura
finetek
usa
torranc
ca
usa
section
transvers
cryostat
hplap
stain
section
fix
ice
cold
paraformaldehyd
wash
three
time
cold
phosphatebuff
salin
place
phosphatebuff
salin
min
rins
room
temperatur
phosphatebuff
salin
wash
alkalin
phosphatas
buffer
moll
ph
moll
nacl
moll
min
excess
liquid
remov
section
sigma
fast
bcipnbt
substrat
solut
sigma
st
loui
mo
usa
appli
section
min
room
temperatur
dark
slide
rins
three
time
room
temperatur
phosphatebuff
salin
dehydr
etoh
min
etoh
min
etoh
min
xylen
min
coverslip
permount
mount
media
fisher
scientif
fair
lawn
nj
usa
imag
captur
use
qicam
olympu
digit
camera
process
use
qcaptur
pro
qimag
bc
canada
hematoxylin
eosin
thick
briefli
fix
methanol
stain
cryosect
stain
gill
hematoxylin
section
wash
dehydr
clear
xylen
mount
permount
sacrific
cpvvaccin
mice
gastrocnemiu
muscl
rapidli
excis
flash
frozen
liquid
nitrogen
frozen
muscl
powder
use
mortar
pestl
protein
extract
proteaseinhibit
buffer
contain
mm
nacl
mm
ph
mm
mm
tween
amersham
complet
proteas
inhibitor
roch
indianapoli
usa
protein
quantifi
via
spectrophotometr
absorpt
use
bradford
reagent
peirc
rockford
il
usa
extract
analyz
hplap
express
use
commerci
luminometri
kit
appli
biosystem
carlsbad
ca
usa
muscl
snap
frozen
liquid
nitrogen
pulver
mortal
pestl
pulver
muscl
tissu
resuspend
tissu
lysi
buffer
nadoc
mm
tri
mm
nacl
triton
proteas
inhibitor
cocktail
sigmaaldrich
st
loui
mo
usa
dna
isol
cell
tissu
lysat
use
dneasi
blood
tissu
kit
qiagen
valencia
ca
usa
accord
manufactur
guidelin
genom
quantif
perform
util
polyaspecif
probe
quantitativepcr
previous
describ
gregorev
et
al
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
